U.S. Markets closed

The Zacks Analyst Blog Highlights: Macy's, Shire, Forest Laboratories, Salix Pharmaceuticals and NPS Pharmaceuticals

Zacks Equity Research

For Immediate Release

Chicago, IL – November 07, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Macy’s, Inc. ( M- Free Report), Shire plc ( SHPG- Free Report), Forest Laboratories ( FRX- Free Report), Salix Pharmaceuticals ( SLXP- Free Report) and NPS Pharmaceuticals, Inc. ( NPSP- Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Wednesday’s Analyst Blog:

Macy's Launches Virtual Recognition App

Bringing in innovation for its tech friendly mobile shoppers Macy’s, Inc. ( M- Free Report) is set to integrate NantMobile’s iD visual recognition technology to launch a new app. The new app named Star Gifts will facilitate customers globally to use visual recognition and shop from Macy’s Star Gifts’ range of products.
With the app, users can simply scan gift advertisements available on magazines, catalogs, bus stands, billboards, subway stations, windowscapes etc and get assistance on product knowledge, gift ideas and a lot more. Shoppers can use the Star Gifts app for free on iTunes and Google Play and gain access to product videos, gift suggestions and related information.
The app users will get a first hand at the new visual content as the Star Gifts catalog will launch sometime during November beginning. To kick start the holiday shopping, customers can also scan first page of the catalog and get a $10 of Macy’s mobile Gift code, with conditions applied. This offer will only be valid until Nov 17, 2013.
This innovation is a significant development in the world of mobile technology, further enhancing Macy’s strong omnichannel capacities as it will add to its existing mobile methods including the stand-alone app, advertising partnerships, reward schemes, mobile support online stores on the company’s website.
The introduction of this virtual recognition will enable shoppers to shop at ease, without disturbing their holiday plans. With the strategic launch of this app and the stores being open on Thanksgiving, Macy’s seems to be geared up to augment its sales this holiday season, giving tough competition to its rivals.

Positive News for Shire

Shire plc ( SHPG- Free Report) announced positive top-line results from two phase III studies on attention deficit and hyperactivity disorder ( ADHD) drug Vyvanse for additional indications.
We note that Shire is developing Vyvanse for additional indications such as the treatment of negative symptoms of schizophrenia and binge eating disorder (:BED).

The two randomized phase III studies were conducted to evaluate the safety and efficacy of Vyvanse compared to placebo in adults suffering from BED. The results from the study showed that Vyvanse was statistically superior to placebo on the primary efficacy analysis while maintaining a safety profile.
Consequently, Shire plans to submit a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for the treatment of BED in adults (ages 18 to 55) by the third quarter of 2014.
We are also encouraged by Shire’s efforts for the label expansion of Vyvanse. We remind investors that Shire holds a strong position in the ADHD market driven by key drugs like Vyvanse, Intuniv and Adderall XR.
Shire’s growth engine is Vyvanse, which accounted for approximately 24.4% of total revenues in the first nine months of 2013. Shire is now focused on exploring Vyvanse outside the U.S. Vyvanse (under trade name Elvanse) was approved in the EU in Dec 2012. Shire plans to capture 75% of the total EU market by 2014.

Shire currently carries a Zacks Rank #1 (Strong Buy). Other stocks that currently look attractive include Forest Laboratories ( FRX- Free Report), Salix Pharmaceuticals ( SLXP- Free Report) and NPS Pharmaceuticals, Inc. ( NPSP- Free Report). All three carry a Zacks Rank #2 (Buy).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on M - FREE
Get the full Report on SHPG - FREE
Get the full Report on FRX - FREE
Get the full Report on SLXP - FREE
Get the full Report on NPSP - FREE
Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on M

Read the analyst report on SHPG

Read the analyst report on FRX

Read the analyst report on SLXP

Read the analyst report on NPSP

Zacks Investment Research